SOURCE: Market Pulse

October 25, 2007 08:30 ET

Market Pulse Breaking News Alert for Thursday, October 25, 2007: ZMS -- Zecotek's Patented LFS Scintillation Crystals Selected for Trials by the Prestigious Paul Scherrer Institute, Switzerland!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Market Pulse.

ATLANTA, GA--(Marketwire - October 25, 2007) - Market Pulse News Alert for this AM, Stocks to Watch are: Zecotek Medical Systems Inc. (TSX-V: ZMS), Transmeta Corp. (NASDAQ: TMTA), Apple Inc. (NASDAQ: AAPL) and Microsoft Corp. (NASDAQ: MSFT).

Investors need to be watching Zecotek Medical Systems Inc. (TSX-V: ZMS) this AM! Zecotek Medical Systems is a bio-photonics company that develops high-performance crystals, photo-detectors, medical lasers, optical imaging and 3D display technologies for commercial applications in the medical diagnostics and high-tech industry. The company has three distinct operating divisions: medical imaging, medical lasers and 3D display and labs located in Canada, Singapore and Russia. Zecotek has developed two significant bio-photonic technologies with the potential to revolutionize the $15 billion medical diagnostics industry. With core competencies in lasers, optoelectronics and crystal growth, Zecotek's Singapore Lab is focused on introducing creative laser solutions to this growing industry. The annual revenue generated by the US medical laser systems market alone, has more than doubled in the past five years and reached $2.5 billion in 2006. ZMS has successfully developed a compact, color 3D display prototype that offers multiple viewers with true volumetric visualization and exhibit depth and parallax over a wide viewing angle. The unique applications of photonics continue to emerge. Those which are established as economically important applications for semiconductor photonic devices include optical data recording, fiber optic telecommunications, laser printing (based on xerography), displays, and optical pumping of high-power lasers. The potential applications of photonics are virtually unlimited and include chemical synthesis, medical diagnostics, on-chip data communication, laser defense, and fusion energy to name several interesting additional examples. Zecotek has a proven track record of securing licensing agreements with industry leaders. The company is creating shareholder value by commercializing novel, patented and patent-pending bio-photonic technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders. ZMS has partnered with the University of Washington to develop a proprietary PET/MRI scanning device, which has the potential to set a new standard in medical imaging. Northrop Grumman has signed a 20-year exclusive agreement to license ZMS' LFS scintillation crystal material. Zecotek recently announced that it has signed a letter of intent with Fujikura Ltd. of Japan to negotiate terms of a proposed business partnership which would feature the manufacture and distribution of certain technologies and products, including Zecotek's new line of fiber lasers and a detector block consisting of Zecotek's proprietary solid-state photo detectors and LFS scintillation crystals. ZMS is poised to become a significant player in the bio-photonics and medical diagnostics industry! Zecotek Medical Systems just had excellent news out in a press release before today's opening bell announcing the Paul Scherrer Institute based in Switzerland has purchased an order of Zecotek's patented Lutetium Fine Silicate (LFS) scintillation crystals for trials in its next-generation Positron Emission Tomography (PET) medical imaging program! Investors need to go to the company's website www.zecotek.com and review its exciting technology's potential! Investors should be watching this one closely!

Zecotek Medical Systems Inc. (TSX-V: ZMS) today announced the Paul Scherrer Institute based in Switzerland has purchased an order of Zecotek's patented Lutetium Fine Silicate (LFS) scintillation crystals for trials in its next-generation Positron Emission Tomography (PET) medical imaging program. The Paul Scherrer Institute PET program is focused on advancing improvements in sensitivity, spatial resolution and image quality in PET scanners, based on the understanding that advances in PET are driven largely by progress in instrumentation, in particular the performance of scintillation materials, photo-detectors and read-out electronics. Higher resolution PET scanners would also widen PET's application in brain function analysis and diagnosis.

"We are delighted that the prestigious Paul Scherrer Institute is working with our LFS scintillation crystals in their program to develop a next generation PET detector module," said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek. "The Institute is well known and highly respected for its work in medical imaging and is representative of the broader market for our LFS scintillation crystals."

Zecotek's patented LFS scintillation material was developed as a high-performance, cost-effective replacement for the materials used in the present generation of PET machines and other medical and non-medical imaging applications. The LFS crystals also complement Zecotek's patented Micro-pixel Avalanche Photo Diodes (MAPD), designed to replace current use photo multiplier tube photo detectors. Both Zecotek's LFS and MAPD offer significant benefits to the diagnostic medical industry. The scintillation material, together with the photo-detector, typically constitutes 50 to 65% of the manufacturing cost of a PET scanner. Both the LFS and MAPD offer increased performance and lowered costs, improving both patient throughput and improved diagnostics in PET and PET-CT (Computed Tomography) applications. The combined use of Zecotek's LFS material and MAPD would also enable an integrated PET-MRI (Magnetic Resonance Imaging) machine.

About Paul Scherrer Institute

The Paul Scherrer Institute is a multi-disciplinary research centre for natural sciences and technology based in Switzerland. In national and international collaboration with universities, other research institutes and industry, it is active in solid state physics, materials sciences, elementary particle physics, life sciences, nuclear and non-nuclear energy research, and energy-related ecology.

The Paul Scherrer Institute develops and operates complex research installations which call for especially high standards of know-how, experience and professionalism, and is one of the world's leading user laboratories for the national and international scientific community. Through its research, the Institute acquires new basic knowledge and actively pursues its application in industry.

About Zecotek

Zecotek Medical Systems is a photonics technology company developing high-performance crystals, photo detectors, medical lasers, optical imaging and 3D display technologies for commercial applications in the medical diagnostics and high-tech industry. Founded in 2003, the company has three distinct operating divisions: medical imaging, medical lasers and 3D display and labs located in Canada, Singapore and Russia. Zecotek commercializes its novel, patented and patent-pending bio-photonic technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders. For more information, please visit www.zecotek.com.

Stocks in the news and acting well as of late include: Transmeta Corp. (NASDAQ: TMTA), Apple Inc. (NASDAQ: AAPL) and Microsoft Corp. (NASDAQ: MSFT).

Information contained herein is the opinion of Market-Pulse.com ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated fifty thousand dollars from Zecotek Medical Systems Inc. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives free trading shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. Market-Pulse.com and Market Pulse Breaking News Alert are owned by Market Pulse LLC.

Contact Information